Tags

Type your tag names separated by a space and hit enter

Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Clin Endocrinol (Oxf). 1984 Aug; 21(2):179-88.CE

Abstract

Chronic treatment with the LHRH agonist D-Ser(TBU)6-LHRH (1-9)-EA (buserelin) has been suggested as a contraceptive method since it has been shown to inhibit ovulation. To elucidate the mechanism of this paradoxical action, we investigated the pattern of gonadotrophin and steroid secretion after the daily intranasal application of 300 micrograms of the agonist. Ten volunteers with ovulatory cycles received the analogue from Day 1 to Day 22 and 5 mg norethisterone acetate from Day 16 to Day 22. Blood samples were taken on Day 1, 15, and 21 every 15 min for 6 h after the application of the agonist. LH secretion was increased nine-fold on the first treatment day as compared to Day 2 of the preceding control cycle. Thereafter, it decreased slowly but was still elevated five-fold on Day 21 of treatment. FSH release increased three-fold on Day 1 but decreased thereafter to values similar to those of the controls. During treatment with the analogue, the LH/FSH ratio changed from 1.3 (controls) to 3.8 on Day 1 and to 5.5 on Day 15 and 21 of treatment. Although the ovary retained follicular activity, ovulation was inhibited in every treatment cycle. This seemed to be due to an impairment of follicular steroid synthesis as indicated by a significant increase of 17 alpha-hydroxyprogesterone and testosterone levels for several hours after the application of the analogue. It appears that at least during the first treatment cycle of daily administration of buserelin the abolishment of pulsatile gonadotrophin release, and the abnormally increased ratio of LH/FSH secretion may possibly impair follicular maturation and thus contribute to the inhibition of ovulation.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6432376

Citation

Kuhl, H, et al. "Contraception With an LHRH Agonist: Effect On Gonadotrophin and Steroid Secretion Patterns." Clinical Endocrinology, vol. 21, no. 2, 1984, pp. 179-88.
Kuhl H, Jung C, Taubert HD. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns. Clin Endocrinol (Oxf). 1984;21(2):179-88.
Kuhl, H., Jung, C., & Taubert, H. D. (1984). Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns. Clinical Endocrinology, 21(2), 179-88.
Kuhl H, Jung C, Taubert HD. Contraception With an LHRH Agonist: Effect On Gonadotrophin and Steroid Secretion Patterns. Clin Endocrinol (Oxf). 1984;21(2):179-88. PubMed PMID: 6432376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns. AU - Kuhl,H, AU - Jung,C, AU - Taubert,H D, PY - 1984/8/1/pubmed PY - 1984/8/1/medline PY - 1984/8/1/entrez KW - Androgens KW - Biology KW - Clinical Research KW - Contraception KW - Contraceptive Mode Of Action KW - Corpus Luteum Hormones KW - Endocrine System KW - Endometrium KW - Estradiol KW - Estrogens KW - Evaluation KW - Family Planning KW - Follicle Stimulating Hormone--analysis KW - Genitalia KW - Genitalia, Female KW - Gonadotropins KW - Gonadotropins, Pituitary--analysis KW - Hormones KW - Human Volunteers KW - Luteinizing Hormone--analysis KW - Ovulation KW - Ovulation Suppression KW - Physiology KW - Pituitary Hormone Releasing Hormones--administraction and dosage KW - Progesterone KW - Reproduction KW - Reproductive Control Agents KW - Research Methodology KW - Testosterone KW - Urogenital System KW - Uterus SP - 179 EP - 88 JF - Clinical endocrinology JO - Clin Endocrinol (Oxf) VL - 21 IS - 2 N2 - Chronic treatment with the LHRH agonist D-Ser(TBU)6-LHRH (1-9)-EA (buserelin) has been suggested as a contraceptive method since it has been shown to inhibit ovulation. To elucidate the mechanism of this paradoxical action, we investigated the pattern of gonadotrophin and steroid secretion after the daily intranasal application of 300 micrograms of the agonist. Ten volunteers with ovulatory cycles received the analogue from Day 1 to Day 22 and 5 mg norethisterone acetate from Day 16 to Day 22. Blood samples were taken on Day 1, 15, and 21 every 15 min for 6 h after the application of the agonist. LH secretion was increased nine-fold on the first treatment day as compared to Day 2 of the preceding control cycle. Thereafter, it decreased slowly but was still elevated five-fold on Day 21 of treatment. FSH release increased three-fold on Day 1 but decreased thereafter to values similar to those of the controls. During treatment with the analogue, the LH/FSH ratio changed from 1.3 (controls) to 3.8 on Day 1 and to 5.5 on Day 15 and 21 of treatment. Although the ovary retained follicular activity, ovulation was inhibited in every treatment cycle. This seemed to be due to an impairment of follicular steroid synthesis as indicated by a significant increase of 17 alpha-hydroxyprogesterone and testosterone levels for several hours after the application of the analogue. It appears that at least during the first treatment cycle of daily administration of buserelin the abolishment of pulsatile gonadotrophin release, and the abnormally increased ratio of LH/FSH secretion may possibly impair follicular maturation and thus contribute to the inhibition of ovulation. SN - 0300-0664 UR - https://www.unboundmedicine.com/medline/citation/6432376/Contraception_with_an_LHRH_agonist:_effect_on_gonadotrophin_and_steroid_secretion_patterns_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0300-0664&date=1984&volume=21&issue=2&spage=179 DB - PRIME DP - Unbound Medicine ER -